Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Vosaroxin for relapsed AML: Updates from VALOR

ASH 2016

Published: 5 Dec 2016

Views: 2135

Rating:

Save

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

Dr Ravandi speaks with ecancertv at ASH 2016 with updates from the VALOR trial of vosaroxin versus placebo in combination with cytarabine.

These results, first reported at ASH 2014, position vosaroxin as a major step forward for elderly patients with relapsed or refractory acute myeloid leukaemia based on its subversion of known resistance pathways.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Molecular profiling in prostate cancer: key challenges for clinical implementation

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer